FOXP3 Modified T-Cells for Autoimmune Disease Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases are inadequate in enhancing and stabilizing the immunosuppressive effects of T-cells, which are crucial for managing autoimmune responses.
Innovation Solution
Introducing a first nucleic acid sequence encoding a FOXP3 polypeptide and a second nucleic acid sequence encoding a binding agent into T-cells, potentially with a receptor polypeptide, to enhance their immunosuppressive functions and direct them to specific tissues, thereby treating autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional T-cell treatments are used, then the basic immunosuppressive function is maintained, but the immunosuppressive effects are insufficient and unstable for effective autoimmune disease treatment
Solution Approach 1:
The patent modifies the FOXP3 protein through specific amino acid mutations (e.g., at positions 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100) to enhance its nuclear localization and transcriptional activity, thereby strengthening the immunosuppressive function of T-cells while maintaining stability
Solution Approach 2:
The patent introduces a binding agent that acts as an intermediary to direct the modified T-cells to specific tissues and organs affected by autoimmune diseases. This binding agent facilitates the homing of T-cells to target sites, enabling localized immunosuppressive action where it is most needed
2Reliability
If T-cells are introduced to treat autoimmune diseases, then immunosuppressive effects are enhanced, but the ability to target specific affected tissues is limited
Solution Approach 1:
The binding agent serves as a mediator that enables the T-cells to recognize and home to specific tissues and organs affected by autoimmune diseases. This intermediary facilitates targeted delivery of immunosuppressive T-cells to the appropriate locations in the body
Solution Approach 2:
The patent enables the T-cells to exhibit different homing capabilities to different tissues and organs based on the binding agent specificity. This allows the T-cells to preferentially accumulate in affected areas (such as joints, gut, or nervous system) while avoiding healthy tissues, providing localized therapeutic action
Data Source
AI summary
Provided herein are methods of increasing T-cell function and T-cells produced by these methods. Also provided herein are methods of treating a subject using T-cells produced by these methods.